Radiosurgery shows promise for kidney cancer

Stereotactic radiosurgery shows promise as a therapeutic option for patients with localized primary renal cancer who are considered poor surgical candidates and who do not have a prior history of pelvic or abdominal radiation, according to research presented at the American Society for Radiation Oncology annual meeting in Boston.

Related Videos

Related Content

Advertisement

February 19th 2025

Level of service for vasectomy prompts coding confusion

Jonathan Rubenstein, MD Mark Painter

"With the requirements for an E/M code as noted above, we agree with you that the supporting documentation, if appropriately documented, would support a level 3 outpatient visit for a visit regarding counseling for contraception or family planning," write Jonathan Rubenstein, MD, and Mark Painter.

February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

February 19th 2025

FDA approves Expanded Access Program to provide alternative source of BCG

Hannah Clarke

According to ImmunityBio, shipments or rBCG are set to begin immediately via the EAP.

January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 18th 2025

PSMA staging is linked with higher rates of ADT, ARPI utilization in prostate cancer

Benjamin P. Saylor

PSMA staging did not appear to have a significant impact on radiation therapy utilization.

February 18th 2025

Belzutifan approved in EU for renal cell carcinoma

Hannah Clarke

The conditional approval of belzutifan is valid for 1 year, with the opportunity for yearly renewal pending forthcoming data.

Related Content

Advertisement

February 19th 2025

Level of service for vasectomy prompts coding confusion

Jonathan Rubenstein, MD Mark Painter

"With the requirements for an E/M code as noted above, we agree with you that the supporting documentation, if appropriately documented, would support a level 3 outpatient visit for a visit regarding counseling for contraception or family planning," write Jonathan Rubenstein, MD, and Mark Painter.

February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

February 19th 2025

FDA approves Expanded Access Program to provide alternative source of BCG

Hannah Clarke

According to ImmunityBio, shipments or rBCG are set to begin immediately via the EAP.

January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 18th 2025

PSMA staging is linked with higher rates of ADT, ARPI utilization in prostate cancer

Benjamin P. Saylor

PSMA staging did not appear to have a significant impact on radiation therapy utilization.

February 18th 2025

Belzutifan approved in EU for renal cell carcinoma

Hannah Clarke

The conditional approval of belzutifan is valid for 1 year, with the opportunity for yearly renewal pending forthcoming data.